NOTE FROM TED: Experiments discussed in this talk should not be performed outside of accredited research settings. Research around psychedelics remains an emerging field of study. TEDx events are independently organized by volunteers. The guidelines we give organizers are described in more detail here: http://storage.ted.com/tedx/manuals/t…
Josh Ismin believes we are at the Tipping Point when it comes to psychedelics to treat mental illness, but thinks the supervised “assisted therapy” model will lack the ability to scale. Josh is the CEO and co-founder of Psylo, an Australian biotech start-up using computational chemistry to produce novel non-hallucinogenic medications inspired-by psychedelics to treat a much broader patient population. Joshua Ismin is the CEO/co-founder of Psylo, with diverse commercial and operational experience. Josh is a repeat founder with extensive fundraising and business building experience across a number of tech start-ups. He holds American and Australian citizenship, and holds an MBA and BSBA from Washington University in St Louis. www.psylo.bio This talk was given at a TEDx event using the TED conference format but independently organized by a local community. Learn more at https://www.ted.com/tedx